Shares of Genmab A/S, which specialises in developing human antibodies for disease, retreated 6.8% to DKK 315 in early trading on the Nordic Stock Exchange on 29 January 2008 following a spike in the price a day earlier. The stock rose on rumours of a possible takeover bid by a large pharmaceutical or biotechnology company.
